InvestSMART

Neurizon Therapeutics Limited (ASX: NUZ) - Announcements

- Current share price for NUZ : $0.063

ASX company news and announcements for Neurizon Therapeutics Limited (NUZ) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurizon Therapeutics Limited (NUZ) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurizon Therapeutics Limited (NUZ), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurizon Therapeutics Limited (NUZ)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$49 Neurizon secures $6million R&D Tax Incentive Rebate 29 Jan 2026 1:12PM $0.084 $0.063 fallen by 25%
$49 Application for quotation of securities - NUZ 29 Jan 2026 9:47AM $0.089 $0.063 fallen by 29.21%
$49 Neurizon Completes Entitlement Offer 27 Jan 2026 9:56AM $0.097 $0.063 fallen by 35.05%
$49 Change of Director's Interest Notice 23 Jan 2026 9:08AM $0.084 $0.063 fallen by 25%
$49 Notification of cessation of securities - NUZ 23 Jan 2026 9:02AM $0.084 $0.063 fallen by 25%
$49 Notice of General Meeting/Proxy Form 21 Jan 2026 9:43AM $0.083 $0.063 fallen by 24.10%
$49 Global Trademark Protection Secured Across Key Markets 20 Jan 2026 9:48AM $0.083 $0.063 fallen by 24.10%
$49 Investor webinar presentation 15 Jan 2026 12:23PM $0.084 $0.063 fallen by 25%
$49 Notice of a Shareholder webinar 8 Jan 2026 9:14AM $0.080 $0.063 fallen by 21.25%
$49 Becoming a substantial holder 7 Jan 2026 10:29AM $0.082 $0.063 fallen by 23.17%
$49 Notification of cessation of securities - NUZ 6 Jan 2026 10:36AM $0.079 $0.063 fallen by 20.25%
$49 Entitlement Offer Opens & Despatch of Offer Booklet 5 Jan 2026 8:54AM $0.082 $0.063 fallen by 23.17%
$49 Section 708A Cleansing Statement 2 Jan 2026 9:32AM $0.085 $0.063 fallen by 25.88%
$49 Regulatory and Development Update 2 Jan 2026 8:47AM $0.085 $0.063 fallen by 25.88%
$49 Change of Director's Interest Notices x4 2 Jan 2026 8:28AM $0.085 $0.063 fallen by 25.88%
$49 Application for quotation of securities - NUZ 31 Dec 2025 10:52AM $0.081 $0.063 fallen by 22.22%
$49 Section 708A Cleansing Statement 23 Dec 2025 12:58PM $0.086 $0.063 fallen by 26.74%
$49 Application for quotation of securities - NUZ 23 Dec 2025 11:51AM $0.088 $0.063 fallen by 28.41%
$49 Notice under s708AA(2)(f) 23 Dec 2025 9:51AM $0.110 $0.063 fallen by 42.73%
$49 Proposed issue of securities - NUZ 23 Dec 2025 9:51AM $0.110 $0.063 fallen by 42.73%
$49 Proposed issue of securities - NUZ 23 Dec 2025 9:50AM $0.110 $0.063 fallen by 42.73%
$49 Equity Raising Presentation 23 Dec 2025 9:50AM $0.110 $0.063 fallen by 42.73%
$49 New Funding Secured for HEALEY ALS Platform Trial 23 Dec 2025 9:49AM $0.110 $0.063 fallen by 42.73%
$49 Trading Halt 19 Dec 2025 9:13AM $0.110 $0.063 fallen by 42.73%
$49 FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial 11 Dec 2025 8:27AM $0.115 $0.063 fallen by 45.22%

51 - 75 of 169 results

Page 3 of 7

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.